Zidesamtinib: Side Effects, Uses & Monitoring
JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and Administration (2
- Data source
- FDA labeling via NIH DailyMed (label 3760e421…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and Administration (2.1 ), Clinical Studies (14.1 )] .
Conditions associated with Zidesamtinib in labeling
Frequently Asked Questions
What is Zidesamtinib used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Zidesamtinib?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Zidesamtinib require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Zidesamtinib.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.